Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan — Yi‐Hsin Chan (2022) | RDL Network
Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan
Article 2022 en
Authors
YC
Yi‐Hsin Chan
TC
Tze‐Fan Chao
SC
Shao‐Wei Chen
Abstract
1 min read
Results of this study suggest that FXa inhibitors were associated with lung injury among patients with NVAF who were treated with OACs. Physicians should be vigilant in monitoring for any potential adverse lung outcomes associated with the use of these drugs.
Professor Gregory Lip, Allison Keshishian, A Kang, X Luo, Nipun Atreja, Y Zhang, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Steven Deitelzweig
Steven Deitelzweig, Allison Keshishian, A Kang, Aaron Jenkins, Nipun Atreja, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Professor Gregory Lip
Steven Deitelzweig, Allison Keshishian, A Kang, Aaron Jenkins, Nipun Atreja, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.